Beta-2_Microglobulin_Testing_Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Beta</strong>-2 microglobulin is a protein of major histocompatibility complex class I molecules, which is<br />
used as tumor marker for certain blood cancers. It is present on all nucleated cells. The beta-2<br />
microglobulin is tested in plasma, serum, or urine samples. The beta-2 microglobulin level in the<br />
sample helps detect disease activity; for example, low level of beta-2 microglobulin in serum<br />
indicates less disease activity, while high levels indicate higher disease activity. In many<br />
hematological disorders, beta-2 microglobulin level works as a highly sensitive marker. <strong>Beta</strong>-2<br />
microglobulin is used as a prognostic marker to test disease activity such as lymphoma, leukemia,<br />
and multiple myeloma. High levels of beta-2 microglobulin in urine samples can help detect tubular<br />
disorders of the kidney. However, this testing cannot be used to diagnose a specific disease. It only<br />
provides additional information regarding a patient’s prognosis.<br />
Request Report TOC @ https://www.transparencymarketresearch.com/beta-2-microglobulintesting-market.html<br />
Driving factors of the global beta-2 microglobulin testing market include rising geriatric population<br />
and increasing prevalence of blood cancer. However, high cost, patent protection, regulatory<br />
constraints, technological edge, and limitations are anticipated to restrain the market. The global<br />
beta-2 microglobulin testing market can be segmented based on application, end-users, sample type,<br />
and region. In terms of application, the market can be divided into kidney diseases, tumor markers,<br />
urinalysis, ELISA, blotting, life science, testing or assay validation, antibody production,<br />
immunoassays, controls, and calibrators & standards. The tumor markers segment held a large<br />
market share in 2016 owing to the high prevalence of cancer. The kidney diseases and urinalysis<br />
segments are anticipated to witness strong growth in the next few years. Growth of these segments<br />
can be attributed to rise in the geriatric population.<br />
Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?<br />
flag=B&rep_id=30443<br />
Based on end-user, the global beta-2 microglobulin testing market can be segmented into hospitals,<br />
academic, and research institutes, and diagnostic centers. The hospitals segment held the major<br />
market share in 2016 due to government initiatives for spreading awareness about the benefits of<br />
pre-determination of cancer. The academic and research institutes segment is expected to gain<br />
market share in the next few years owing to high demand for advancements in research &<br />
development.<br />
In terms of sample type, the global beta-2 microglobulin testing market can be classified into urine,<br />
blood, and cerebrospinal fluid. The blood sample segment accounted for high market share in 2016,<br />
attributed to rising prevalence of lymphoma, multiple myeloma, infections such as HIV,<br />
cytomegalovirus, and inflammatory disorders. The urine sample segment is anticipated to grow<br />
during the forecast period owing to rising population of people above 50 years and increasing<br />
prevalence of kidney disorders.<br />
Geographically, the global beta-2 microglobulin testing market can be divided into Asia Pacific,<br />
Europe, North America, Latin America, and Middle East & Africa. North America held the largest<br />
share of the beta-2 microglobulin test market in 2016, owing to the technological advancements,<br />
which have created numerous opportunities for determining specific tumors, monitoring biological<br />
response to cancer therapy, and genetic predisposition. Increasing geriatric population further fueled<br />
the market in the region. Europe held the second largest market share in 2016 owing to the high<br />
prevalence of cancer. The market in Asia Pacific is expected to witness strong growth during the<br />
forecast period due to increasing awareness and government initiatives in India and China.<br />
Key players in the global beta-2 microglobulin testing market are Becton, Dickinson and Company,
Bio-Rad Laboratories, Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd., Abbott<br />
Laboratories, Sequenom, QIAGEN, Cepheid, Biomedical diagnostics, bioMérieux, Inc., and other<br />
prominent players.<br />
Pre Book full report @ https://www.transparencymarketresearch.com/checkout.php?<br />
rep_id=30443<ype=S<br />
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a global market intelligence company providing business<br />
information reports and services. The company’s exclusive blend of quantitative forecasting and<br />
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s<br />
experienced team of analysts, researchers, and consultants use proprietary data sources and various<br />
tools and techniques to gather and analyze information.<br />
TMR’s data repository is continuously updated and revised by a team of research experts so that it<br />
always reflects the latest trends and information. With extensive research and analysis capabilities,<br />
Transparency <strong>Market</strong> Research employs rigorous primary and secondary research techniques to<br />
develop distinctive data sets and research material for business reports.<br />
Contact<br />
Transparency <strong>Market</strong> Research<br />
State Tower,<br />
90 State Street,<br />
Suite 700,<br />
Albany NY - 12207<br />
United States<br />
Tel: +1-518-618-1030<br />
USA - Canada Toll Free: 866-552-3453<br />
Website: https://www.transparencymarketresearch.com/<br />
Blog: http://www.tmrblog.com/
Change language